Cullinan Therapeutics (CGEM) Stock Price, News & Analysis

Company Overview

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $8.29 to $8.77
• 50-Day Range: $7.13 to $9.08
• 52-Week Range: $6.85 to $21.01
• Volume: 227,089 shs
• Average Volume: 546,937 shs
• Market Capitalization: $490.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Cullinan Therapeutics Stock Analysis - MarketRank™

Cullinan Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 1565th out of 1,880 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cullinan Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cullinan Therapeutics is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cullinan Therapeutics is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cullinan Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.20% of the float of Cullinan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cullinan Therapeutics has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Cullinan Therapeutics has recently increased by 3.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cullinan Therapeutics does not currently pay a dividend.

Dividend Growth

Cullinan Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.20% of the float of Cullinan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cullinan Therapeutics has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Cullinan Therapeutics has recently increased by 3.17%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.80

News Sentiment

Cullinan Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cullinan Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cullinan Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.07% of the stock of Cullinan Therapeutics is held by insiders.

Percentage Held by Institutions

86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CGEM Stock Analysis - Frequently Asked Questions

How have CGEM shares performed this year?

Cullinan Therapeutics' stock was trading at $12.18 at the beginning of the year. Since then, CGEM shares have decreased by 31.7% and is now trading at $8.32.
View the best growth stocks for 2025 here.

How were Cullinan Therapeutics' earnings last quarter?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04.

When did Cullinan Therapeutics IPO?

Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Cullinan Therapeutics' major shareholders?

Top institutional investors of Cullinan Therapeutics include Vanguard Group Inc. (5.15%), Siren L.L.C. (2.02%), Siren L.L.C. (2.02%) and Braidwell LP (1.66%). Insiders that own company stock include Vision Scs F2, Bioscience I 2017 Ltd F2, Nadim Ahmed, Jeffrey Alan Jones, Corrine Savill, Jennifer Michaelson and Jeffrey Trigilio.
View institutional ownership trends.

How do I buy shares of Cullinan Therapeutics?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cullinan Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/17/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEM
• CIK: 1789972
• Web: www.cullinanoncology.com
• Phone: 617-410-4650
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: +260.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$167.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.47%
• Return on Assets: -28.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.62
• Quick Ratio: 11.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.14 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 59,010,000
• Free Float: 55,433,000
• Market Cap: $490.96 million
• Optionable: Optionable
• Beta: -0.04